echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hengrui Medicine's PD-1+LAG-3 combination therapy is approved, how is the progress in the clinical LAG-3 field?

    Hengrui Medicine's PD-1+LAG-3 combination therapy is approved, how is the progress in the clinical LAG-3 field?

    • Last Update: 2022-01-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 1, the CDE official website showed that Hengrui Medicine's carrelizumab+famitinib+SHR1802 combination therapy was approved for clinical use in advanced solid tumors


    SHR1802 is a LAG3 monoclonal antibody


    In China, although 10 companies have deployed this target, it is still in the early stage of clinical development


    Global R&D layout

    Global R&D layout

    LAG-3 is mainly expressed on activated T cells and some NK cells, and negatively regulates the cell proliferation, activation and homeostasis of T cells


    According to the Insight Global New Drug Database, there are currently as many as 40 antibody drugs targeting LAG-3 under development, including 27 monoclonal antibodies, 12 double antibodies, and 1 fusion protein


    Global R&D Status of LAG-3 Target

    From: Insight database (http://db.


    As of December 1, 2021

    Bristol-Myers Squibb's Relatlimab is the first LAG-3 inhibitory monoclonal antibody to enter the clinic


    Based on this clinical practice, BMS submitted a BLA application to the FDA in September this year and was granted priority review qualifications


    Merck and MacroGenics are the two competitors whose progress is closest to BMS


    China's R&D is still in its early stages

    China's R&D is still in its early stages

    According to the Insight database, a total of 13 new drugs targeting LAG-3 are under development in China


    Domestic research and development progress of LAG3 target

    Finished by Insight, as of December 1, 2021

    Take PD-(L)1+LAG-3 combination therapy as an example.


    Although Junshi Biopharmaceuticals did not have a self-developed LAG-3 antibody drug that entered the clinic, it has teamed up with Wei Li Zhibo to launch a phase I clinical trial of teriprizumab combined with LAG-3 monoclonal antibody LBL-007 for the first-line treatment of melanoma, and Phase Ib/II clinical trials of a variety of solid tumors


    In the development of the LAG3 target, Shimai Pharmaceutical's DNV3 has also adopted a differentiated development strategy for indications.


    In the field of double antibodies, in addition to Cinda’s IBI323 and Zai Lab’s MGD-013, it also includes the EMB-02 of Anmai Bio, which is the fastest-growing one among domestic companies’ independent research and development of PD-1/LAG3 double antibodies.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.